Annual Review

Overview

The report presents 2023 as a year of strong growth, with net sales of 4,082 million USD and 8.5% constant-currency growth. It highlights scientific scale through over 770 clinical trials, more than 650 R&D professionals and over 160 major regulatory approvals since 2019. On ESG, the company describes group-wide priorities, renewable electricity at three factories and a carbon-neutrality objective across its plants.

Document

Report type: Annual Report with Sustainability Disclosures
Class: Embedded
Scope: Full report
Fiscal year: 2023
Language: English
Pages
File size

Reporting standards, commitments and assurance details are available with a free account.

Materiality

Assessment
Basis

Assurance

Statement included

Data Services

Turn sustainability reports into a dataset built for your research.

From bulk PDFs to structured indicators and machine-readable documents.

View services